196 related articles for article (PubMed ID: 18679628)
1. Oncolytic adenoviruses for cancer gene therapy.
Liu TC; Thorne SH; Kirn DH
Methods Mol Biol; 2008; 433():243-58. PubMed ID: 18679628
[TBL] [Abstract][Full Text] [Related]
2. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis.
Dorer DE; Nettelbeck DM
Adv Drug Deliv Rev; 2009 Jul; 61(7-8):554-71. PubMed ID: 19394376
[TBL] [Abstract][Full Text] [Related]
3. Replicative adenoviruses for cancer therapy.
Alemany R; Balagué C; Curiel DT
Nat Biotechnol; 2000 Jul; 18(7):723-7. PubMed ID: 10888838
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic adenoviruses expressing interleukin: a novel antitumour approach.
Pei DS; Zheng JN
Expert Opin Biol Ther; 2010 Jun; 10(6):917-26. PubMed ID: 20402550
[TBL] [Abstract][Full Text] [Related]
5. Insulated hsp70B' promoter: stringent heat-inducible activity in replication-deficient, but not replication-competent adenoviruses.
Rohmer S; Mainka A; Knippertz I; Hesse A; Nettelbeck DM
J Gene Med; 2008 Apr; 10(4):340-54. PubMed ID: 18265421
[TBL] [Abstract][Full Text] [Related]
6. Replication-dependent transgene expression from a conditionally replicating adenovirus via alternative splicing to a heterologous splice-acceptor site.
Carette JE; Graat HC; Schagen FH; Abou El Hassan MA; Gerritsen WR; van Beusechem VW
J Gene Med; 2005 Aug; 7(8):1053-62. PubMed ID: 15756711
[TBL] [Abstract][Full Text] [Related]
7. A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor.
Carette JE; Graat HC; Schagen FH; Mastenbroek DC; Rots MG; Haisma HJ; Groothuis GM; Schaap GR; Bras J; Kaspers GJ; Wuisman PI; Gerritsen WR; van Beusechem VW
Virology; 2007 Apr; 361(1):56-67. PubMed ID: 17184803
[TBL] [Abstract][Full Text] [Related]
8. A demand for next-generation oncolytic adenoviruses.
Hermiston T
Curr Opin Mol Ther; 2006 Aug; 8(4):322-30. PubMed ID: 16955695
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic viruses as therapeutic agents.
Wildner O
Ann Med; 2001 Jul; 33(5):291-304. PubMed ID: 11491186
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated cancer gene therapy and virotherapy (Review).
Fukazawa T; Matsuoka J; Yamatsuji T; Maeda Y; Durbin ML; Naomoto Y
Int J Mol Med; 2010 Jan; 25(1):3-10. PubMed ID: 19956895
[TBL] [Abstract][Full Text] [Related]
11. Virus combinations and chemotherapy for the treatment of human cancers.
Kumar S; Gao L; Yeagy B; Reid T
Curr Opin Mol Ther; 2008 Aug; 10(4):371-9. PubMed ID: 18683102
[TBL] [Abstract][Full Text] [Related]
12. ReVOLT: radiation-enhanced viral oncolytic therapy.
Advani SJ; Mezhir JJ; Roizman B; Weichselbaum RR
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):637-46. PubMed ID: 17011442
[TBL] [Abstract][Full Text] [Related]
13. Selectively replicating oncolytic adenoviruses as cancer therapeutics.
Yu DC; Working P; Ando D
Curr Opin Mol Ther; 2002 Oct; 4(5):435-43. PubMed ID: 12435044
[TBL] [Abstract][Full Text] [Related]
14. The potential of oncolytic virus therapy for pancreatic cancer.
Kasuya H; Takeda S; Nomoto S; Nakao A
Cancer Gene Ther; 2005 Sep; 12(9):725-36. PubMed ID: 15818382
[TBL] [Abstract][Full Text] [Related]
15. In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments.
Escutenaire S; Cerullo V; Diaconu I; Ahtiainen L; Hannuksela P; Oksanen M; Haavisto E; Karioja-Kallio A; Holm SL; Kangasniemi L; Ribacka C; Kauppinen S; Joensuu T; Arstila TP; Pesonen S; Kanerva A; Hemminki A
Ann Med; 2011 Mar; 43(2):151-63. PubMed ID: 21261555
[TBL] [Abstract][Full Text] [Related]
16. Development of transcriptionally regulated oncolytic adenoviruses.
Ko D; Hawkins L; Yu DC
Oncogene; 2005 Nov; 24(52):7763-74. PubMed ID: 16299536
[TBL] [Abstract][Full Text] [Related]
17. E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer.
Fukuda K; Abei M; Ugai H; Kawashima R; Seo E; Wakayama M; Murata T; Endo S; Hamada H; Hyodo I; Yokoyama KK
Cancer Gene Ther; 2009 Feb; 16(2):126-36. PubMed ID: 18818710
[TBL] [Abstract][Full Text] [Related]
18. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.
Pühler F; Willuda J; Puhlmann J; Mumberg D; Römer-Oberdörfer A; Beier R
Gene Ther; 2008 Mar; 15(5):371-83. PubMed ID: 18200068
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the E3 and L3 regions for arming oncolytic adenoviruses to achieve a high level of tumor-specific transgene expression.
Robinson M; Ge Y; Ko D; Yendluri S; Laflamme G; Hawkins L; Jooss K
Cancer Gene Ther; 2008 Jan; 15(1):9-17. PubMed ID: 17853920
[TBL] [Abstract][Full Text] [Related]
20. The potential impact of hypoxia on the success of oncolytic virotherapy.
Hay JG
Curr Opin Mol Ther; 2005 Aug; 7(4):353-8. PubMed ID: 16121701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
